Get the Stockscreener App
13.40
3.11%
-0.43
Generate Biomedicines Inc stock is traded at $13.40, with a volume of 321.19K.
It is down -3.11% in the last 24 hours and down -17.44% over the past month.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
See More
Previous Close:
$13.83
Open:
$13.88
24h Volume:
321.19K
Relative Volume:
0.42
Market Cap:
$1.72B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-6.2169
EPS:
-2.1554
Net Cash Flow:
-
1W Performance:
-1.18%
1M Performance:
-17.44%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.22
$14.08
1-Week Range:
$13.22
$14.58
52-Week Range:
$11.00
$18.18
Generate Biomedicines Inc Stock (GENB) Company Profile
Name
Generate Biomedicines Inc
Sector
Industry
Phone
888-469-0055
Address
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.40 | 1.72B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | H.C. Wainwright | Buy |
| Mar-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-24-26 | Initiated | Goldman | Buy |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Mar-24-26 | Initiated | Morgan Stanley | Overweight |
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
View All
Generate Biomedicines Inc Stock (GENB) Latest News
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
What Just Happened with Generate Biomedicines' IPO - Kavout | AI
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Nvidia Invests in Biotech Company Generate Biomedicines - Intellectia AI
Significant Drop for Generate Biomedicines (GENB) as Shares Decl - GuruFocus
Generate Biomedicines Plunges As Rally Suddenly Unwinds - TipRanks
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
GENBGenerate Biomedicines Inc Dividends - Finviz
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price to book forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to book forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Q&A: Generate Biomedicines CTO talks AI advancements - TechTarget
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Value Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000E Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2500 Value Benchmark - marketscreener.com
Generate Biomedicines (GENB) Holds Near Support as Biotech Sector Shows Mixed SignalsPut Spread Alert - Bölüm Sonu Canavarı
Generate Biomedicines stock ends week back above IPO price as volume jumps - TechStock²
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market - The Motley Fool
Transcript : Generate Biomedicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 03 - marketscreener.com
Enterprise value to EBITDA forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Drone startup Elroy Air to list on Nasdaq via $1 billion SPAC deal - Reuters
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (NASDAQ:GENB) - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (BOATS:GENB) - TradingView
Price to sales forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Price to earnings forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Boosts Generate Biomedicines Price Target to 22 Dollars - sekbernews.id
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts - Sahm
Generate Biomedicines (GENB) Surges 9.7%: Key Levels and What Lies AheadPrice Action Signals - dars.gov.et
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P TMI Index - marketscreener.com
Generate Biomedicines Inc Stock (GENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Generate Biomedicines Inc Stock (GENB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):